CombiMatrix (NASDAQ: CBMX) provides molecular diagnostic solutions and comprehensive clinical support to foster the highest quality in patient care. The company specializes in prenatal diagnostics, miscarriage analysis /recurrent pregnancy loss, pediatric genetics and pre-implantation genetic screening, offering DNA-based testing for the detection of genetic abnormalities beyond what can be identified through traditional methodologies. CombiMatrix performs genetic testing utilizing a variety of advanced cytogenomic techniques, including chromosomal microarray, standardized and customized fluorescence in situ hybridization (FISH) and high-resolution karyotyping. For more information, visit the company’s website at www.combimatrix.com